Protara Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Protara Therapeutics, Inc. (TARA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$8.45 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-07
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$13.37M, a 185.64% decline year-over-year.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $4.91M.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $15.33M, a 66.28% increase year-over-year.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$906.00K, a 103.93% decline year-over-year.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $19.92M.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$11.33M.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$12.48M, a 557.76% decline from fiscal 2013.
- Protara Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $2.73M, a 63.06% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$13.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$8.45M 10-Q · filed 2017-08-07 | $6.87M derived: sum of 3 quarters · filed 2017-08-07 | $5.97M derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | $4.91M 10-Q · filed 2017-05-10 | $20.24M derived: sum of 2 quarters · filed 2017-05-10 | $19.34M derived: sum of 3 quarters · filed 2017-05-10 | $34.95M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-12-31 | $15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $14.42M derived: sum of 2 quarters · filed 2017-03-16 | $30.03M derived: sum of 3 quarters · filed 2017-08-07 | $19.92M 10-K · filed 2017-03-16 |
| 2016-09-30 | -$906.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $14.70M derived: sum of 2 quarters · filed 2017-08-07 | $4.59M 10-Q · filed 2016-11-07 | $13.81M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-06-30 | $15.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $5.49M 10-Q · filed 2017-08-07 | $14.71M derived: sum of 3 quarters · filed 2017-08-07 | $37.77M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | -$10.12M 10-Q · filed 2017-05-10 | -$897.00K derived: sum of 2 quarters · filed 2017-05-10 | $22.16M derived: sum of 3 quarters · filed 2017-05-10 | $33.74M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $32.27M derived: sum of 2 quarters · filed 2017-03-16 | $43.85M derived: sum of 3 quarters · filed 2017-03-16 | -$11.33M 10-K · filed 2017-03-16 |
| 2015-09-30 | $23.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $34.63M derived: sum of 2 quarters · filed 2016-11-07 | -$20.55M 10-Q · filed 2016-11-07 | -$16.87M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $11.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$43.61M 10-Q · filed 2016-08-08 | -$39.93M derived: sum of 3 quarters · filed 2017-03-16 | -$41.61M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$55.18M 10-Q · filed 2016-05-09 | -$51.50M derived: sum of 2 quarters · filed 2017-03-16 | -$53.19M derived: sum of 3 quarters · filed 2017-03-16 | -$70.02M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.99M derived: sum of 2 quarters · filed 2017-03-16 | -$14.84M derived: sum of 3 quarters · filed 2017-03-16 | -$12.48M 10-K · filed 2017-03-16 |
| 2014-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$18.52M derived: sum of 2 quarters · filed 2015-11-12 | -$16.16M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$16.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$14.48M 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $2.35M 10-Q · filed 2015-05-13 | |||
| 2013-12-31 | $2.73M 10-K · filed 2016-03-14 | |||
| 2012-12-31 | $7.38M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |